Questions: Vaccines and Vaccination Strategies

Question 1

A patient with severe combined immunodeficiency (SCID) needs protection against measles. Which vaccine approach is contraindicated, and why?

• A. The inactivated (killed) vaccine — killed pathogens are too immunogenic for immunocompromised patients
• B. The mRNA vaccine — mRNA could permanently alter the patient's gene expression
• C. The live-attenuated vaccine — even the weakened pathogen could replicate and cause serious disease without functional immune defenses
• D. The subunit vaccine — purified proteins cannot be safely administered without a functioning immune system

Answer: (C)

Live-attenuated vaccines use a weakened but still replicating form of the pathogen. In immunocompetent patients, the immune system controls this replication and builds strong memory. In immunocompromised patients (like SCID), the attenuated pathogen cannot be controlled and may replicate unchecked, causing vaccine-strain disease. Inactivated vaccines, mRNA vaccines, and subunit vaccines are non-replicating and are generally safe in immunocompromised patients (though they may be less effective due to impaired immune responses). Option B reflects a common misconception: mRNA is rapidly degraded and cannot integrate into the genome.

Question 2

Subunit vaccines often require adjuvants to produce effective immunity. What is the primary reason purified protein antigens alone are insufficient?

• A. Purified proteins are too small to be recognized by B cell receptors without adjuvant enhancement
• B. Adjuvants increase the concentration of antigen in lymph nodes by slowing its clearance from the injection site
• C. Purified proteins are too 'clean' — they lack the pathogen-associated molecular patterns that activate innate immunity and provide the danger signals dendritic cells need to fully activate T cells
• D. Adjuvants prevent the immune system from developing tolerance to the foreign protein

Answer: (C)

The adaptive immune response requires two signals: antigen recognition (signal 1) and co-stimulation triggered by innate immune activation (signal 2). Pathogen infections naturally provide danger signals — PAMPs like LPS, flagellin, or dsRNA — that activate pattern recognition receptors and put dendritic cells into an activated, antigen-presenting state. Purified proteins provide antigen but no danger signals, leading to inadequate T cell activation or even tolerance. Adjuvants (aluminum salts, TLR agonists, oil emulsions) artificially provide the innate activation that the protein alone lacks. Option B is partially true (depot effect) but is not the primary mechanistic reason.

Question 3

mRNA vaccines introduce genetic material that can integrate into the patient's genome and permanently alter their DNA.

• T. True
• F. False

Answer: False

This is a widespread misconception. mRNA vaccines deliver messenger RNA, which is transcribed in the cytoplasm — it never enters the nucleus and therefore cannot interact with or integrate into chromosomal DNA. mRNA is also chemically unstable and is degraded by cellular ribonucleases within days. Integration requires reverse transcriptase (to convert RNA back to DNA) and integrase enzymes, which are not present in human cells outside of specific contexts. The protein antigen produced from the mRNA is displayed on the cell surface, triggering the immune response, and then cleared along with the mRNA itself.

Question 4

Live-attenuated vaccines typically produce stronger and more durable immune responses than inactivated vaccines, because the attenuated pathogen replicates and sustains antigen exposure over time.

• T. True
• F. False

Answer: True

Sustained antigen exposure from replicating live-attenuated pathogens drives more robust germinal center reactions, deeper somatic hypermutation, stronger affinity maturation, and better memory cell generation than the brief antigen pulse from a non-replicating killed preparation. Live-attenuated vaccines (measles, MMR, yellow fever, oral polio) also stimulate both humoral and cellular immunity more effectively, often with a single dose or small number of doses. The tradeoff is safety: replication capacity that makes them more immunogenic in healthy individuals is precisely what makes them dangerous in immunocompromised patients.

Question 5

Why is it insufficient for a vaccine to simply generate circulating antibodies? What additional immunological goals must an effective vaccine achieve for lasting protection?

Model answer: Antibody generation alone is insufficient for several reasons. First, antibody titers wane over months to years; lasting protection requires long-lived memory B cells that can rapidly regenerate high-affinity antibodies upon re-exposure. Second, those antibodies must be high-affinity — achieved through germinal center reactions, somatic hypermutation, and affinity maturation. Low-affinity antibodies may not neutralize the pathogen effectively. Third, intracellular pathogens (viruses, Mycobacterium tuberculosis) require cytotoxic T cells (CD8+) that antibodies cannot reach; a vaccine must also generate appropriate memory CD8+ T cells. Fourth, the T helper polarization must match the threat: Th1 for intracellular pathogens, Th2 for extracellular parasites. A vaccine that generates the wrong Th profile may provide inadequate protection even with normal antibody levels.

Effective vaccination engineers an entire immune response — from initial innate activation through germinal center maturation to memory cell generation — not just antibody production. The route of administration, adjuvant, and antigen form all influence which memory populations are generated and how durable they are. This is why vaccine development is complex: the goal is not a detectable antibody titer at the time of measurement, but a durable, high-quality immune memory that can be rapidly recalled years later.